KE

Kimball Electronics, Inc. (KE) - Q3 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026 (Fiscal Q3 2026) and the nine months ended March 31, 2026. Kimball Electronics, Inc. is a global provider of electronics manufacturing services (EMS) and contract manufacturing organization (CMO) solutions serving automotive, medical, and industrial markets. The company operates as a single reportable segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 6% in Q3 and 4% year-to-date (YTD) compared to the prior year. This was driven by single-digit declines across all verticals (Automotive, Medical, Industrial).
• Margin Expansion: Despite lower sales, gross margin improved to 7.9% in Q3 (from 7.2% prior year) and 8.0% YTD (from 6.7% prior year). Improvements were driven by efficiencies from restructuring, favorable exchange rates in Europe, and the maturing of a new braking program.
• Profitability Surge: Net income increased 50% in Q3 and 87% YTD. This was primarily due to lower restructuring expenses ($0.9M in Q3 vs. $2.0M prior year) and reduced interest expense due to lower borrowings and rates.
• Restructuring: The company recorded $4.1M in restructuring expenses YTD, primarily for workforce resizing and the Tampa facility closure. The Tampa closure is substantially complete, with the facility sold in April 2026 for $22 million.
• Vertical Performance:
  • Automotive: Down 3% QoQ and 9% YTD due to loss of a major program and tariff impacts.
  • Medical: Down 8% QoQ but up 5% YTD, offset by a step-up in sales with the largest medical customer.
  • Industrial: Down 8% QoQ and 5% YTD, driven by declines in climate controls and residential HVAC.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue investing in capabilities, including a new Indianapolis facility and capacity expansions. They anticipate incurring an additional $1.5 million to $3.0 million in restructuring costs through fiscal year 2027.
• Liquidity: The company maintains a strong balance sheet with a current ratio of 2.1 and debt-to-equity of 0.3. Total available liquidity (cash + unused credit facilities) is approximately $358.5 million.
• Recent Credit Facility Update: On April 30, 2026, the company amended its primary credit facility, extending the revolving maturity to April 30, 2031, and modifying the debt covenant to consider global unrestricted cash up to $25 million.
• Risks: Key risks include global economic conditions, geopolitical tensions (Middle East), tariffs and trade barriers, supply chain disruptions, and the ability to recover tariff-related costs from customers.
• Open Orders: Open orders declined 6% to $602 million as of March 31, 2026.

Investor Verification Checklist

• Tampa Facility Sale: Verify the final proceeds and impact on the balance sheet from the April 2026 sale of the Tampa assets ($22M proceeds vs. $6.6M carrying value).
• Tariff Recovery: Assess the company's ability to fully pass through tariff costs to customers, as noted in management commentary.
• Customer Concentration: Review the impact of the top three customers (Nexteer Automotive, Philips, ZF), which collectively represent a significant portion of net sales.
• Restructuring Costs: Monitor the execution of the remaining $1.5M–$3.0M in expected restructuring costs through FY2027.
• Capital Expenditures: Track the $43.2M in YTD capital expenditures, specifically the new Indianapolis medical facility, to ensure alignment with projected revenue growth.